FarmaKology-Nanoform Collaborates with Takeda on Plasma-derived Therapy Development

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+21K Subs.

Today's Company

Lykos Therapeutics

Lykos Therapeutics, our mission is to transform mental healthcare. We’re applying decades of evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a Public Benefit Company, we are focused on delivering positive impact on our people, communities and society.

News

NSG BioLabs and Merck Collaborates to Support Biotech Start-ups to Advance Research & Innovations

NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, and the Life Science business of Merck Singapore, announce partnership giving biotech start-ups access to resources and expertise to bolster the research and development capabilities of NSG Biolabs' tenants, thereby facilitating opportunities for funding, partnerships, production, and commercialization.

Nanoform Collaborates with Takeda on Plasma-derived Therapy Development

Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte and Syndax Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs.).

iniuva and Enamine Announce Strategic Collaboration to Advance Drug Discovery for Rare Genetic Diseases

iniuva GmbH, a Hamburg-based pioneering biotech startup specializing in AI-powered drug discovery, and Enamine Ltd, a Kyiv-based leading provider of chemical compounds and related services, today announced a collaborative research and development program.The collaboration aims to revolutionize the efficiency and precision of small-molecule drug discovery, particularly in the realm of orphan drugs and pharmacological chaperones.

Research & Study

Antibiotics Could Target Bacterial Protein Found to Maintain Envelope Integrity

Researchers Hope to Use Vitamins to Displace Antibiotics and Zinc Oxide in Addressing Piglet Diarrhea

AI Tools Struggle with Patient Descriptions of Genetic Conditions

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Maximize Brand Success with Data-Driven Provider Market Insights

Accelerating Translational Research with High-Performance Automated InSituPlex® Assays

Video